Motilal Oswal: Torrent Pharma Q2 Review - Operating Leverage Drives Profitability
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Torrent Pharmaceuticals Ltd. delivered in-line Q2 FY21 results.
Revival in the domestic formulations and Germany businesses was offset by muted growth in the U.S. and currency headwinds in Brazil.
Reduced opex kept profitability elevated. With the outlook for India/Germany/Brazil improving, the company is expected to outperform the industry on new launches/ better traction in existing products.
Growth in the U.S. hinges on the Dahej/Indrad regulatory resolution.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.